Patents by Inventor Paul G. Schmidt

Paul G. Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030125263
    Abstract: This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
    Type: Application
    Filed: September 30, 2002
    Publication date: July 3, 2003
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Larry Gold, Paul G. Schmidt, Nebojsa Janjic
  • Patent number: 6465188
    Abstract: This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: October 15, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Larry Gold, Paul G Schmidt, Nebojsa Janjic
  • Patent number: 6412601
    Abstract: A suspendible container for holding items that is capable of being attached to holes on a horizontal surface. The container is particularly adaptable to being attached to the top cap of a ladder. The container includes at least one prong which attaches to the container and is removably insertable into a hole in the horizontal surface. The container is particularly suited for holding items such as tools and paint cans that would be needed by the user of a ladder.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: July 2, 2002
    Inventor: Paul G. Schmidt
  • Publication number: 20020043429
    Abstract: A suspendible container for holding items that is capable of being attached to holes on a horizontal surface. The container is particularly adaptable to being attached to the top cap of a ladder. The container includes at least one prong which attaches to the container and is removably insertable into a hole in the horizontal surface. The container is particularly suited for holding items such as tools and paint cans that would be needed by the user of a ladder.
    Type: Application
    Filed: March 7, 2000
    Publication date: April 18, 2002
    Applicant: VOLPE AND KOENIG, P.C.
    Inventor: Paul G. Schmidt
  • Patent number: 6147204
    Abstract: This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: November 14, 2000
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Paul G Schmidt, Nebojsa Janjic
  • Patent number: 6011020
    Abstract: This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.
    Type: Grant
    Filed: May 4, 1995
    Date of Patent: January 4, 2000
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Larry Gold, Paul G. Schmidt, Nebojsa Janjic
  • Patent number: 5817334
    Abstract: A composition and method are provided for the making of cholesterol containing phospholipid liposomes such that when dried and then reconstituted, the liposomes retain their structure and size distribution as well as substantially all of the material that was originally encapsulated, and they behave biologically in a normal fashion. The cryoprotective agents are used in the aqueous medium to hydrate the phospholipid(s) and are a combination of at least one sugar and at least one protein, polypeptide, and/or oligopeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Paul G. Schmidt, Gary Fujii
  • Patent number: 5328678
    Abstract: Liposomes with hyperosmotic concentration of compounds encapsulated therein are targeted to tumors for neutron capture therapy. The compounds have an element with a large neutron capture cross section and an isotope that emits alpha particles when bombarded with neutrons. A method employing such liposomes for neutron capture therapy is also described.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: July 12, 1994
    Assignee: Vestar, Inc.
    Inventors: Gary Fujii, Paul G. Schmidt, Ronald C. Gamble
  • Patent number: 5320906
    Abstract: Delivery vehicles comprising an outer biocompatible encapsulating layer, an inner amphiphilic active ingredient-associated layer and an active ingredient are described. The delivery vehicles are biocompatible and are capable of solubilizing the active ingredient for in vivo delivery to bodily tissue or other bodily systems. Uses include nuclear magnetic resonance imaging and therapeutic drug delivery.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: June 14, 1994
    Assignee: Vestar, Inc.
    Inventors: Crispin G. S. Eley, Paul G. Schmidt, Gary Fujii
  • Patent number: 5258499
    Abstract: Delivery vehicle formulations comprise active agents encapsulated within liposomal vesicles to which are attached protein hormones (ligands) such as interleukin-2. The ligands are capable of showing affinity for specific cell receptors resulting in delivery of the encapsulated active agent to target cells, enabling delivery of active agents to particular cell populations in the treatment of conditions such as immune system disorders.
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: November 2, 1993
    Assignee: Vestar, Inc.
    Inventors: Paula J. Konigsberg, Leroy L. Richer, Paul G. Schmidt, Joseph A. Uliana
  • Patent number: 4728575
    Abstract: An agent for contrast enhancement in nuclear magnetic resonance imaging is disclosed. Micellular particles such as phospholipid vesicles are associated with or enclose a paramagnetic material. The particles may be formulated with an agent, such as cholestrol, to promote vesicle stability and water exchange across the vesicle bilayer. The vesicles may or may not have antibodies or other cell recognition targeting agents attached to the surface to provide specific targeting. The vesicles provide enhanced target specificity, reduced burden of toxic contrast material and amplified contrast enhancement.
    Type: Grant
    Filed: April 10, 1985
    Date of Patent: March 1, 1988
    Assignee: Vestar, Inc.
    Inventors: Ronald C. Gamble, Paul G. Schmidt